Dallas, TX -- (SBWIRE) -- 03/12/2013 -- Marketbuzzreport.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-
PBF Energy Inc. (NYSE:PBF) decreased 3.95% and closed at $37.89 on a traded volume of 1.19 million shares. So far this year, the stock is up over 36%. The 52-week range for the stock is $25.88 and $42.50. PBF Energy Inc., is a petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants and other petroleum products in the United States.
Get Latest News, Updates on PBF Here
Valero Energy Corporation (NYSE:VLO) moved down 3.91% and closed at $43.72 on a traded volume of 22.84 million shares. The 52-week range for the stock is $20.0 and $48.97. The Company said a hydrocracking unit at its oil refinery in Benicia, California was shut Sunday due to an upset at the plant's hydrogen plant. Valero's Benicia refinery is able to process up to 132,000 barrels of crude oil a day.
Is VLO a Strong Buying Opportunity After The Recent Slump? Find out Here
Cliffs Natural Resources Inc. (NYSE:CLF) went down 3.64% and closed at $23.83 on a traded volume of 8.34 million shares. The Company expects to idle its Wabush Pointe Noire pellet plant within the city of Sept-Iles in Quebec by the end of the second quarter of 2013. The Company indicated that its decision to idle its iron ore pellet operation is due to high production costs and lower pellet premium pricing which is expected to persist in certain markets during the year.
Cliffs Natural Resources has been reiterated by TheStreet Ratings as a hold with a ratings score of C-.
Is CLF Signaling a Buy After The Sudden Gain? Don’t Miss Out Free Trend Analysis Here
Celldex Therapeutics, Inc. (NASDAQ:CLDX) went down 3.49% and closed at $11.89 on a traded volume of 3.01 million shares. The Company posted fourth quarter loss of $16.8 million or 27 cents per share compared to loss of $12.7 million or 29 cents per share in the same quarter a year earlier. Revenue increased 50% to $3.6 million. The analysts, on average, expected a loss of 25 cents per share on $2.5 million in revenue. Research and development expenses jumped 40% to $13.7 million on higher costs related to a potential brain cancer treatment that the company is developing.
Is CLDX Signaling a Buy After The Sudden Gain? Don’t Miss Out Free Trend Analysis Here
Marketbuzzreport.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Marketbuzzreport.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.marketbuzzreport.com
The assembled information disseminated by Marketbuzzreport.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Marketbuzzreport.com does expect that investors will buy and sell securities based on information assembled and presented in Marketbuzzreport.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)